Trevi Therapeutics Prices $50 Million Underwritten OfferingNew Haven, Conn., December 16, 2024 – Trevi Therapeutics, Inc. (Nasdaq: TRVI) recently announced the pricing of an underwritten offering, amounting to $50 million. The offering entails 12,500

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Trevi Therapeutics’s 8K filing here.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.